VERTEX PHARMACEUTICALS INC / MA

Evaluation of Disclosure Controls and Procedures

Our management (under the supervision and with the participation of our chief executive officer and chief financial

officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and

15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly

Report on Form 10-Q, has concluded that, based on such evaluation, as of September 30, 2026 our disclosure controls and

procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is

recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing

and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no

matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives,

and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible

controls and procedures.

Changes in Internal Controls Over Financial Reporting

On September 1, 2026, we completed the Crinetics Acquisition, which was accounted for as a business combination. As

a result, Crinetics operations have been included in our condensed consolidated statements of income since September 1,

While we are currently in the process of evaluating and integrating Crinetics' historical internal controls over financial

reporting with ours, no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)

under the Securities Exchange Act of 1934, as amended) occurred during the three months ended September 30, 2026 that

have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.